Markus U. Diethelm

Markus U. Diethelm was the CEO of Sandoz at the time of the 1996 merger and became the first Chairman of the Board of Novartis. His defining moment was the recognition that Sandoz, despite its long history, lacked the scale to compete independently in the emerging era of blockbuster drug development. His decision to merge with Ciba-Geigy, a rival company, was a radical move that required overcoming deep-seated cultural differences and personal rivalries, ultimately creating one of the world's largest pharmaceutical companies.

Markus U. Diethelm is a Swiss business executive who served as the CEO of Sandoz from 1991 to 1996 and as the first Chairman of the Board of Novartis from 1996 to 1999. He was the primary architect of the 1996 merger between Sandoz and Ciba-Geigy, a transaction that created Novartis and reshaped the global pharmaceutical industry. Diethelm's career at Sandoz spanned over three decades, during which he held various leadership positions in finance and operations. His leadership style was characterized by a focus on financial discipline and strategic long-term planning, qualities that were essential in navigating the complex integration of the two companies. After stepping down as Chairman of Novartis in 1999, Diethelm remained active in the business community, serving on the boards of several major Swiss corporations. He is widely respected in Switzerland for his role in creating a global pharmaceutical leader and for his commitment to maintaining the company's headquarters in Basel.